Biosimilars Pipeline Report: A guide for understanding the growing market

By Sean McGowan |

Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. To date, there have been 28 approvals and 18 launches in the U.S. biosimilar market. As this market matures, its pipeline continues to grow.

This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market. 

Enter Your Information to Access the 2020 Biosimilar Pipeline Report

             
   

       

       

       

       



 
By submitting this form, I hereby consent to the receipt of marketing materials from AmerisourceBergen and its affiliates via email and other forms of communications.

 


About the Author

Sean McGowan

Senior Director, Biosimilars
AmerisourceBergen
View Bio